Hyderabad, October 15, 2016: Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Aripiprazole tablets, USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, a therapeutic equivalent generic version of Abilify® (aripiprazole) tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).
The Abilify® brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.
Dr. Reddy’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are available in bottle count sizes of 30.
Abilify® is a registered trademark of Otsuka Pharmaceutical Company.
Corporate Comm India(CCI Newswire)
